Bank of New York Mellon
MTNB icon

Bank of New York Mellon’s Matinas BioPharma MTNB Stock Holding History

Bank of New York Mellon’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-403
Closed -$3.19K – 4143
2024
Q2 		$3.19K Hold
403
– – ﹤0.01% 4117
2024
Q1 		$5.46K Sell
403
-1,400
-78% -$16.6K ﹤0.01% 4137
2023
Q4 		$19.5K Hold
1,803
– – ﹤0.01% 4241
2023
Q3 		$11.7K Sell
1,803
-1,500
-45% -$18.4K ﹤0.01% 4285
2023
Q2 		$59.4K Sell
3,303
-10
-0.3% -$233 ﹤0.01% 4150
2023
Q1 		$77.9K Hold
3,313
– – ﹤0.01% 4115
2022
Q4 		$82.8K Sell
3,313
-12
-0.4% -$399 ﹤0.01% 4153
2022
Q3 		$106K Hold
3,325
– – ﹤0.01% 4186
2022
Q2 		$131K Sell
3,325
-64
-2% -$2.44K ﹤0.01% 4173
2022
Q1 		$136K Hold
3,389
– – ﹤0.01% 4342
2021
Q4 		$171K Hold
3,389
– – ﹤0.01% 4324
2021
Q3 		$220K Hold
3,389
– – ﹤0.01% 4174
2021
Q2 		$131K Sell
3,389
-280
-8% -$12K ﹤0.01% 4180
2021
Q1 		$193K Sell
3,669
-322
-8% -$21.6K ﹤0.01% 4066
2020
Q4 		$271K Hold
3,991
– – ﹤0.01% 3868
2020
Q3 		$153K Hold
3,991
– – ﹤0.01% 3901
2020
Q2 		$154K Hold
3,991
– – ﹤0.01% 3854
2020
Q1 		$120K Buy
3,991
+900
+29% +$54.3K ﹤0.01% 3839
2019
Q4 		$351K Hold
3,091
– – ﹤0.01% 3740
2019
Q3 		$97K Hold
3,091
– – ﹤0.01% 4031
2019
Q2 		$132K Buy
3,091
+1,970
+176% +$94.7K ﹤0.01% 3990
2019
Q1 		$61K Sell
1,121
-34
-3% -$1.83K ﹤0.01% 4074
2018
Q4 		$34K Hold
1,155
– – ﹤0.01% 4106
2018
Q3 		$53K Hold
1,155
– – ﹤0.01% 4112
2018
Q2 		$25K Sell
1,155
-2,382
-67% -$68.8K ﹤0.01% 4156
2018
Q1 		$135K Buy
3,537
+30
+0.9% +$1.59K ﹤0.01% 4004
2017
Q4 		$203K Buy
3,507
+182
+5% +$11.7K ﹤0.01% 3946
2017
Q3 		$219K Sell
3,325
-6
-0.2% -$400 ﹤0.01% 3845
2017
Q2 		$282K Buy
+3,331
New +$447K ﹤0.01% 3834

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Bank of New York Mellon's MTNB Position: Q3 2024 in Review

Bank of New York Mellon sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 403 shares — an estimated $3.19K sold.

Bank of New York Mellon first reported a position in MTNB in Q2 2017 and held it in 29 quarters. The position peaked at $351K in Q4 2019. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

  • Bank of New York Mellon reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 403 Matinas BioPharma shares in Q3 2024, an estimated $3.19K.
  • Bank of New York Mellon first reported a position in Matinas BioPharma in Q2 2017 and held it in 29 quarters.
  • Bank of New York Mellon's Matinas BioPharma position peaked at $351K in Q4 2019.
  • 18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Bank of New York Mellon's 13F filing for Q3 2024, filed 12 Nov 2024.